Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

NCT01239459 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Impairment

Interventions

DRUG: Teriflunomide HMR1726
DRUG: Cholestyramine

Sponsor

Sanofi